Cocrystal Pharma Inc (COCP)

In October 2025, Cocrystal Pharma received a $500,000 NIH SBIR award and completed a private placement for $1.03 million. In November 2025, the company reported its Q3 2025 financial results and planned to begin a norovirus challenge study for CDI-988 in Q1 2026, also an initial Phase 2a study of CC-42344 for influenza A was completed, showing a favorable safety profile, but efficacy analyses were not reported due to trial conduct issues. In December 2025, Cocrystal Pharma received IRB approval for its Phase 1b human challenge study with CDI-988 for norovirus. In March 2026, the first subjects were dosed in its Phase 1b norovirus challenge study evaluating CDI-988, and the company reported its 2025 financial results, with a net loss of $8.8 million. The stock price as of March 25, 2026, was $1.08, representing a decline of 24.48% over the previous year.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company with no approved commercial products, so there is no direct demand seasonality for its products and services. The company's focus on antiviral therapeutics for diseases like influenza and norovirus suggests that once products are commercialized, demand for them could be seasonal. The company's stock performance has shown some historical seasonality, with November typically being the strongest month and April the weakest, based on 15 years of data.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases, utilizing a proprietary structure-based drug discovery platform. The company operates within the Biotechnology industry, specifically Pharmaceutical Preparations, and is focused on developing treatments for influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses (HCV). Major product candidates include CDI-988, CC-42344, an Influenza A/B Program, and CC-31244.

Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, and has an office in Miami, Florida, both in the United States. The company also has an international presence through Cocrystal Pharma Australia, Pty LTD, located in Melbourne, VIC, Australia.

Cocrystal Pharma's reputation is driven by its scientific advancements, clinical trial progress, and financial stability. The company has issued press releases detailing positive developments in its drug-development programs, such as favorable safety and tolerability data and the initiation of new clinical trials. The receipt of an NIH SBIR award also serves as external validation of its technology. While there was a setback with the efficacy analysis of an initial Phase 2a influenza study due to trial conduct issues, the company has announced plans for an additional study, indicating a commitment to its pipeline. Financial reports have shown a reduction in net loss and R&D expenses.

As of March 27, 2026, Cocrystal Pharma, Inc. has 29 institutional owners and shareholders holding a total of 770,583 shares, with major institutional shareholders including Vanguard Group Inc and Renaissance Technologies Llc. Institutional investors own 6.72% of Cocrystal Pharma's stock. Individual insiders hold 33.8% of the company's shares, with Phillip Frost being a significant individual owner with 14% ownership.